T Cell News and Research

Latest T Cell News and Research

Two UT Southwestern researchers to receive 2013 Edith and Peter O'Donnell Award

The Academy of Medicine, Engineering, and Science of Texas (TAMEST) announced that two UT Southwestern Medical Center researchers are among the four chosen for the 2013 Edith and Peter O'Donnell Awards.

12 Dec 2012

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.

12 Dec 2012

Autism associated with reductions in cellular adhesion molecules in the blood

A new study published in Biological Psychiatry suggests that autism is associated with reductions in the level of cellular adhesion molecules in the blood, where they play a role in immune function.

12 Dec 2012

SIRT6 protein may play a critical role in blocking cancer and controlling cellular metabolism

A new study sheds more light on how an anti-aging gene suppresses cancer growth, joint University of Michigan Health System and Harvard Medical School research shows.

11 Dec 2012

AC253 drug appears to restore memory in Alzheimer's brain cells

Medical researchers at the University of Alberta have discovered a drug intended for diabetes appears to restore memory in Alzheimer's brain cells.

11 Dec 2012

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Dementia is the umbrella term used to describe a number of neurodegenerative brain disorders that cause progressive changes in thinking abilities and behaviour. The kind of deficits experienced by individuals diagnosed with dementia depends on the location and severity of the pathology in the brain.

11 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

New coronavirus can infect cells from humans and bats alike

The SARS epidemic of 2002-2003 was short-lived, but a novel type of human coronavirus that is alarming public health authorities can infect cells from humans and bats alike, a fact that could make the animals a continuing source of infection, according to a study to be published in in mBio-, the online open-access journal of the American Society for Microbiology, on December 11.

11 Dec 2012

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

A nanomaterial engineered by researchers at Duke can help regulate chloride levels in nerve cells that contribute to chronic pain, epilepsy, and traumatic brain injury.

11 Dec 2012

Pomalidomide safe and effective in treating multiple myeloma

A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.

11 Dec 2012

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.

11 Dec 2012

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

11 Dec 2012

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).

11 Dec 2012

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

Research unveils key gaps in continuity of care for sickle cell patients

Research unveiling key gaps in continuity of care for sickle cell patients transitioning from pediatric to adult care will be presented this week during the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge.

11 Dec 2012

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

Lack of TDP-43 protein can lead to frontotemporal dementia/ALS

Researchers at Mayo Clinic in Florida have uncovered a toxic cellular process by which a protein that maintains the health of neurons becomes deficient and can lead to dementia.

11 Dec 2012

T Cell News and Research

Latest T Cell News and Research

Two UT Southwestern researchers to receive 2013 Edith and Peter O'Donnell Award

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

Autism associated with reductions in cellular adhesion molecules in the blood

SIRT6 protein may play a critical role in blocking cancer and controlling cellular metabolism

AC253 drug appears to restore memory in Alzheimer's brain cells

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

New coronavirus can infect cells from humans and bats alike

Carbon nanotubes can help regulate chloride levels in nerve cells that contribute to neural injuries

Pomalidomide safe and effective in treating multiple myeloma

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Janssen announces U.S. prescribing information update for EDURANT tablets

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Research unveils key gaps in continuity of care for sickle cell patients

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

Lack of TDP-43 protein can lead to frontotemporal dementia/ALS

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in